Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss the company's upcoming presentation at the Animal Longevity Summit in Toronto, where it will showcase results from its Age Dogs trial evaluating centenarian SIRT6 gene therapy. Leire said the invitation to present at the independent scientific event offers important external validation of Genflow's methodology and data quality, giving leading scientists and longevity researchers the chance to scrutinise the dataset. He stressed the October timing reflects the conference schedule rather than any delay, with the company continuing to analyse trial data and hold confidential discussions with animal health companies. Looking ahead, Leire said investors should watch for findings on both sarcopenia and longevity, and how results from aged dogs could translate into Genflow's human sarcopenia programme. "We demonstrated that we have efficacy in mice. Now, we demonstrated that we have efficacy in dogs," he said. "What about human and how can we extrapolate this data from this dog study into human use." For more videos featuring company leaders, industry insights and market updates, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #GenflowBiosciences #EricLeire #SIRT6 #GeneTherapy #Longevity #AnimalLongevity #Biotech #Sarcopenia #mRNATherapeutics #mRNALNP #Acuitas #AgeDogsTrial #HealthcareInnovation #LifeSciences #ProactiveInvestors